Cargando…
Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
Large pharmaceutical companies have withdrawn from antibiotic R&D because of the high risk of failure and because antibiotics are less profitable than other areas; small and medium-sized enterprises (SMEs), which now drive antibiotic R&D, face difficulty securing funding for preclinical and...
Autores principales: | Anderson, M, Panteli, D, Mossialos, E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595735/ http://dx.doi.org/10.1093/eurpub/ckad160.640 |
Ejemplares similares
-
What Works overviews: Opportunities and Challenges
por: Van Dale, D, et al.
Publicado: (2023) -
What can we learn from the effects of the COVID-19 pandemic on hospital care for children in Germany?: Nicole Mauer
por: Mauer, N, et al.
Publicado: (2022) -
The development of HTA collaboration at European level and the challenge of the EU regulation
por: Ruether, A, et al.
Publicado: (2022) -
1.C. Workshop: What has the EU ever done for my health system? Using EU tools effectively for health system change
Publicado: (2022) -
What are the tools provided by the EU to support health and care improvement?
por: Mauer, N
Publicado: (2022)